Skip to content
value.today

Kodiak Sciences Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to bookPrice to book of Biotechnology: $488 M to $1.9 B, median $716 M$0 M$1.5 B$3.1 B$4.6 B$6.2 BMarket value $5.7 B

Your own DCF model

A full discounted-cash-flow model of Kodiak Sciences Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Kodiak Sciences Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Kodiak Sciences Inc.Applied toValue (25th to 75th)Companies
Price to book3.1× / 4.5× / 12.3×36.5×book equity $157 M$488 M to $1.9 B70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Kodiak Sciences Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to book

36.5×

Now above its median of 6.1×, in the top quarter of its range; range 0.3× to 36.5× over 30 months.

0×9×18×27×36×2020202120222023202420252026Price to book 36×Median 6×

as of Oct 22, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 22, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025—$-230 M$-136 M$1 M$-137 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024—$-176 M$-117 M$0 M$-118 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023—$-260 M$-154 M$41 M$-196 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022—$-334 M$-206 M$37 M$-243 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021—$-267 M$-182 M$17 M$-199 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020—$-133 M$-83 M$4 M$-87 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $5.7 B on Oct 22, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.